CannaLean Biotechs Ltd., founded in 2017 and headquartered in Israel,
CannaLean has established an active partnership with our main shareholders:
Mor Research Applications, the tech transfer company of CLALIT HEALTH SERVICES,
The largest HMO in Israel, with over 4.5M members, (14 full-scale hospitals specializing in all fields of medicine, as well as over 2000 community clinics with over 9000 employed physicians).
CannaLean is committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from Dyslipidemia.
CannaLean has 2 indications in it’s clinical trial pipeline:
the first solution is targeting hypercolesterodemia (high cholesterol blood levels) and is estimated to start on Q3-4 2020
the second solution is targeting hypertriglyceriddemia (high triglycerides blood levels) and is estimated to start later on 2020-2021
CannaLean has completed various in vivo and pre-clinical studies showing a significant decrease in cholesterol/triglyceride blood levels, demonstrating the potential clinical effect of the novel patent-protected formulation.
A provisional patent named CANNABIDIOL AND CHITOSAN COMPOSITIONS AND METHODS OF USING THE SAME was filed on 2017 by Mor Research Applications, the Tech Transfer Company of Clalit Health Services. a PCT was filed on October 2018 and is now on the international stage.
The patent covers a composition comprising cannabidiol (CBD) and chitosan for improving dyslipidemia and other signs and symptoms of metabolic syndrome.